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Background: The tools are currently limited in predicting which pa-
tients with an infection will progress to severe sepsis, shock, or
death. The Systemic Inflammatory Response Syndrome (SIRS) criteria,
while part of the definition of sepsis, are not adequately sensitive or
specific to be used alone to predict the clinical course of a patient
[1]. A predictive biomarker could be helpful to clinicians to risk-
stratify infected patients to an appropriate level of care. As a candi-
date biomarker of sepsis, fibrin D-dimer has demonstrated sensitivity
for sepsis in ICU patients, however limiting application of the data to
Emergency patients [2,3]. If the correlation of D-dimer levels with ill-
ness severity described in ICU patients could be reproduced in the
Emergency population, the D-dimer could be used to better risk
stratify patients with infections into appropriate levels of care [4].
The aim was to study the level of D-dimer in patients with presumed
sepsis and the prevalence of organ dysfunction, death and intensive
care unit (ICU) admission in patients with presumed sepsis with D-
dimer levels > = 0.5 μg/ml(FEU).
Materials and methods: Sixty adult patients (18 years and above) pre-
senting to the Emergency, from November 2012 and march 2014, with
a suspected infection (radiographic, laboratory, or clinical findings indi-
cating a need for antibiotics) and at least two out of four SIRS criteria
excluding patients with a history of thromboembolic disease, recent
surgery, renal disease, malignancy, pregnant women were studied pro-
spectively in an observational study and evaluated by a semi-
quantitative D-dimer assay and Sepsis-related Organ Failure Assess-
ment (SOFA) score on day 0, 2 and 30.Observations were made regard-
ing Admission to In-Patient Ward, Average length of stay (days), ICU
Admission, Average ICU stay (days), Organ Dysfunction in the Emer-
gency, Organ Dysfunction at 48 hours (only for In-Patients), In-hospital
death, Organ Dysfunction during 30 day follow up (only for In-Patients),
30-Day Mortality Rate, 30-Day Survival Rate. Association between D-
Dimer levels and organ dysfunction, ICU admission and mortality was
evaluated on day 0 and day 2. Correlation between D-dimer levels and
Sofa score was evaluated on day 0 and day 2.
Results: All the 60 patients (i.e. 100 %) were admitted in In-Patient
Wards. The mean length of in-patient stay of patients was 7.43 days
(±4.07) ranging from a minimum of 1 day to 32 days. Among the 60
patients analysed, 21 patients (35 %) required ICU Admission. The
mean length of ICU stay of patients was 4.87 days (±6.08) ranging
from a minimum of 1 day to 29 days. Out of 60, 36 patients (60 %)
presented with organ dysfunction in Emergency, 19 patients (31.7 %)
had organ dysfunction at 48 hours and 1 patient (1.7 %) had suc-
cumbed to death by 48 hours. The In-hospital Mortality and 30 Day
Mortality was the same 4 out of 60 patients (6.7 %). The 30-day sur-
vival rate was found to be 93.3 %. The higher the D-dimer levels on
day 0 and day 2, the higher the percentage of patients with organ
dysfunction on that respective day (Figs. 1 and 2).© 2016 The Author(s). Open Access This artic
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(http://creativecommons.org/publicdomain/zeThe higher the D-dimer levels on day 0 and day 2, the higher the
percentage of patients who require ICU admission during 30 day
period (Figs. 3 and 4).
The higher the D-dimer on day 0 and day 2, the higher the percent-
age of patients who succumbed to death during 30-day period
(Figs. 5 and 6).
In patients with presumed sepsis, 66.7 % patients had positive D-dimer
levels on day 0 which was found to have a statistically significant asso-
ciation with organ dysfunction at presentation (p value <0.001) and ICU
admission (p value <0.01), respectively. However, the association of D-
dimer levels on day 0 with mortality was not statistically significant (p
value ≥ 0.05). On day 2, positive D-dimer levels were demonstrated to
have a statistically significant association with organ dysfunction on
day 2 (p value <0.001) and ICU admission (p value <0.01), respectively.
However, the association of D-dimer levels on day 2 with mortality was
not statistically significant (p value ≥ 0.05). A positive strong correlation
was demonstrated between D-dimer levels and SOFA Scores both on
Day 0 (Pearson’s correlation coefficient r = .850, p < .001) and Day 2
(Pearson’s correlation coefficient r = .870, p < .001) (Figs. 7 and 8).
Conclusions: It can be concluded that fibrin D-dimer is a promising
biomarker that may identify, in a simple and rapid way, infected pa-
tients who are at increased risk for organ dysfunction, ICU admission
and death; thus helping in triage. These patients, consequently, could
require special attention upon admission to the emergency service.le is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
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Fig. 3 (abstract P1). Distribution of ICU requirement across the
range of D-dimer levels on day 0. (n = 60)
Fig. 4 (abstract P1). Distribution of ICU admission across the range
of D-dimer levels on day 2. (n = 60)
Fig. 5 (abstract P1). Distribution of Mortality across the range of
D-dimer levels on day 0. (n = 60)
Fig. 6 (abstract P1). Distribution of Mortality across the range of
D-dimer levels on day 2. (n = 60)
Fig. 7 (abstract P1). Scatter Plot showing SOFA Score on Day 0 as a
function of D-dimer levels on Day 0
Fig. 8 (abstract P1). Scatter Plot showing SOFA Scores at 48 hrs
(Day 2) as a function of D-dimer levels at 48 hrs (Day 2)
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Background: Differentiating patients who are infected or not in the
intensive care unit (ICU) can be very difficult. Present diagnostic tests
remain inadequate. CD64 has been found to be a potentially useful
marker to identify infected patients. Unfortunately, CD64 measured
by standard flow cytometers in a laboratory takes hours to perform.
The Accellix table top flow cytometer automates the process: sample
preparation and reading are performed in a dedicated disposable
cartridge, and analytical data processing utilizing proprietary algo-
rithms provides answers directly to the user. The purpose of this
study was to evaluate the Accellix CD64 instrument, which provides
results in 20 minutes in ICU patients with and without infections.
Materials and methods: The Accellix disposable cartridge-based plat-
form implements sample preparations using three reagent blisters.
The three Accellix CD64 cartridge blisters contain staining cocktail of
conjugated monoclonal antibodies, lysis buffer and reference beads
respectively. Once sample processing is complete, the sample flows
through a dedicated reading channel where data is acquired. In-
fected (ICUi) and non-infected ICU patients (ICU Control-ICUc) and
normal volunteers (C) had CD64 levels measured by the Accellix
CD64 instrument. Measurements were calculated as ‘CD64 index’, i.e.
the ratio between the fluorescence of the PMN population and the
Critical Care 2016, Volume 20 Suppl 1 Page 3 of 11fluorescence of control beads. ICU infection, ICU control and normal
control patients’ results can be seen in Fig. 9.
Results: 72 subjects were studied (ICUi- 27, ICUc-22 and C-23). CD64
Index levels were higher (mean ± SEM) in ICU infection patients then
ICU control and normal control patients (2.62 ± 0.39 vs. 1.31 ± 0.24 vs.
0.46 ± 0.04, p < 0.01 for ICUi vs. ICUc, p < 0.001 for ICUi vs. C).
Conclusions: CD64 Index levels are higher in infected than non-
infected ICU patients. Accellix CD64 is a promising instrument to
differentiate infected from non-infected ICU patients in a timely
manner.Fig. 9 (abstract P2).
Fig. 10 (abstract P3). Total level of PhCAs, μM
Table 1 (abstract P3). Baseline clinical, laboratory












1 vs 2 2 vs 3
N (M/F) 17 (10/7) 46 (26/20) 14 (10/4) - -
Age, years 48 (38–63) 58 (48–71) 62 (53–67) 0.103 0.521





















SOFA score - 7 (3–9) 14 (12–16) - <0.001
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Background: Previously it has been shown that phenylcarboxylic
acids (PhCAs) could have microbial origin in human blood [1], associ-
ated with mortality [2] and demonstrated biological activity [3]. It is
known that neutrophil dysfunction is one of the key mechanisms of
severe infection and sepsis development.
Objectives: to determine PhCAs levels typical for different severity of
bacterial infection and the ability of these clinically relevant concen-
trations of PhCAs to affect the neutrophil phagocytosis in-vitro.
Materials and methods: Blood samples were collected from outpa-
tients (n = 17) with local bacterial infection of skin and soft tissue
(ISST) and from critically ill patients with documented infection (n =
60): 46 patients on the day of admission to ICU and 14 - in terminal
state one day before death. Clinical and laboratory data, SOFA Scores
in patients were matched. Serum levels of PhCAs were measured
using gas chromatography with flame ionization detector. Data from
the previous study in healthy adult donors (n = 72) were used as a
control [4]. The effect of PhCAs on the function of peripheral blood
neutrophils was assessed by measuring the number of latex beads
(d = 1.5 μm) phagocytized in-vitro, blood samples from healthy volun-
teers (n = 30). Data were compared by Mann–Whitney U-test and
Sign test, Spearman's rank correlation coefficient was defined, p <
0.05 was considered significant (STATISTICA 10).
Results: Levels of PhLA, p-HPhLA and p-HPhAA in patients were sig-
nificantly higher than in healthy donors, as in severe infections and
local bacterial inflammatory processes (Fig. 10, Table 1).
A positive correlation with serum levels of the PhCAs and SOFA were
found (r = 0.645-0.740, p < 0.001). In vitro we observed a significant
decrease in the number of phagocytic neutrophils by 15 % under
the influence of 6.0 μM p-HPhAA and 6.0 μM PhLA. Intensity of the
absorption capacity of neutrophils significantly decreased by: 14 %,
31 % under the influence of 0.6, 6.0 μM p-HPhLA, respectively;23 % - 0.6 μM PhLA; 31 %, 30 % - 0.6, 6.0 μM p-HPhAA, respectively.
Perhaps, the ability of bacteria to produce PhCAs is one of adaptive
mechanisms to protect from effector cells of immune system.
Conclusions: Serum levels of PhCAs reflect the severity in ICU’s pa-
tients and reach maximum values in terminally ill patients with infec-
tion. In-vitro PhCAs are able to inhibit phagocytic activity of neutrophils
in clinically significant concentrations.
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Fig. 11 (abstract P4). Influence of phenolic acids on oxidative
metabolism in liver mitochondria (a), tissue homogenates (b) and
removing their inhibitory effect by N-acetylcysteine (c). Optical dens-
ity of reduced NBT in the presence of 5 mM substrate and 100 μM
phenolic acid – benzoic (BZ), phenyllactic (PL), p-hydroxyphenyllactic
(HPL), phenylacetic (PA), p-hydroxyphenylacetic and phenylpropionic
(PP) acids is presented. Inhibitors of NAD-dependent oxidation rote-
none and N-ethylmaleimide (NEM) confirm the substrate specificity
of NBT reduction. Antioxidant N-acetylcysteine (1 mM) prevents the
inhibition induced by phenolic acids. * р < 0,05 compared with the
corresponding control.
Fig. 12 (abstract P4). Contribution of phenolic acids and cytokines
to the mitochondrial dysfunction. Cytokines indirectly (through
signaling molecules) inhibit pyruvate dehydrogenase and induce NO
and ROS production. Some of bacterial phenolic acid directly inhibit
NAD-dependent oxidation and regulate ROS production
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Background: Mitochondrial dysfunction is inherent in many sys-
temic pathologies, including the inflammatory syndrome and sep-
sis. It is assumed that mitochondrial dysfunction in sepsis is
associated with the overproduction of cytokines, reactive oxygen
species (ROS), and NO, which affects several enzymes and com-
plexes of the respiratory chain. However, the role of bacterial me-
tabolites, which can accumulate in the blood of patients with
infection, is not considered. Differences in the serum level of
phenolic metabolites, in septic patients, compared with healthy
donors was shown earlier [1]. It was found that these compounds
affect the mitochondrial respiration and ROS production, showing
either the prooxidant or antioxidant effects depending on their
chemical structure [2,3]. In this work we studied the effect of
bacterial phenolic acids on the activity of mitochondrial oxidative
enzymes in the liver and kidney.
Materials and methods: The experiments were performed on
male Wistar rats. Liver mitochondria were isolated by the stand-
ard method. Concentrated homogenates (1 g tissue/ml medium)
were prepared from the liver and kidney by a rapid procedure in-
volving cooling, punching through press, and homogenization in
a medium (125 mM KCl, 30 mM HEPES, pH 7.4). The effect of
phenolic acids (all from Sigma) on the oxidation activity of mito-
chondria (0.5 mg protein/ml) and homogenate (1 mg protein/ml)
was assessed by the reduction of nitroblue tetrazolium (NBT) at a
wavelength of 560 nm after a 10-min incubation in the presence
of an oxidation substrate followed by the addition of 20 μl of
10 % Triton X-100.
Results: Phenolic acids influenced mitochondrial oxidative activity
differently depending on the chemical structure of phenolic com-
pounds and the oxidation substrate. Benzoic, phenylacetic, and phe-
nylpropionic acids inhibited NAD-dependent oxidation by 40 % and
weakly decreased succinate oxidation, while p-hydroxyphenyllactate
and p-hydroxyphenylacetate activated NBT reduction supported by
succinate and glutamate oxidation (Fig. 11). Similar effects were de-
tected on tissue homogenates and were more pronounced in the
liver than in the kidney. The antioxidant N-acetylcysteine prevented
inhibition, indicating the contribution of thiol groups and ROS pro-
duction to the decrease in oxidative activity induced by phenolic
acids.
Conclusions: Aromatic bacterial metabolites can be involved in
the development of the mitochondrial failure. Some phenolic
acids inhibit NAD-dependent oxidation. Their action is tissue-
specific. The influence of these phenolic acids is similar in some
respect to the action of proinflammatory cytokines (Fig. 12). Thus,
phenolic acids may regulate the signaling action of interleukins
by affecting the respiration and ROS production in mitochondria
and neutrophils [3].
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Critical Care 2016, Volume 20 Suppl 1 Page 5 of 11Background: The prognosis of patients with severe sepsis or sep-
tic shock is improving. In our center, although promoting the
standardization and individualization of sepsis treatment, some
patients die. We examined the better factor of the prognosis of
septic patients.
Materials and methods: We included the patients with severe sepsis
and septic shock who admitted from the emergency department to
the ICU from January 2014 to June 2015. We defined severe sepsis as
patients with SOFA score 2 points worse than sepsis onset before.
Gender, age, APACHE2, SOFA, time from sepsis onset to our center
visits, and time from sepsis onset to the first antibiotic administra-
tion, were examined.
Results: The number of patients was 60: non-survivor 18(30 %), and
survivor 42(70 %). Table 2 showed characteristics of each group.
As APACHE2 or SOFA was bad, life prognosis was bad. As the defini-
tive treatment or the first antibiotic administration was earlier, life
prognosis was better.
Table 3 showed the way patients' visited the center.
Conclusions: The number of patients was 60: non-survivor 18(30 %),
and survivor 42(70 %).
Table 2 showed characteristics of each group.
As APACHE2 or SOFA was bad, life prognosis was bad. As the defini-
tive treatment or the first antibiotic administration was earlier, life
prognosis was better.






Male : Female 10 : 8 19 : 23
Age 70.9 ± 11.0 73.1 ± 13.7 p =
0.543
APACHE 2 29.2 ± 8.5 17.8 ± 7.2 p <
0.01
SOFA score 12.4 ± 2.9 17.8 ± 7.2 p <
0.01
Time from sepsis onset※ to our
center visits (days)
5.5 ± 6.3 2.9 ± 4.6 p =
0.081
Time from sepsis onset※ to the
first antibiotic administration (days)
4.3 ± 6.0 1.9 ± 4.3 p =
0.071
※ sepsis onset: we estimated the timing of emerging organ dysfunction, such
as impaired consciousness and respiratory difficulty





Introduce from other hospitals after
patient state worsening
9 (50) 12 (28.6)
Introduce from other hospitals
immediately after patients’ visit
6 (33.3) 20 (47.6)
Directly transport to our center 3 (16.7) 8 (19.0)P6
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Critical Care 2016, 20(Suppl 1):P6Background: Sepsis, a leading cause of death in the ICU, is character-
ized by detrimental inflammation and multiple organ failure. We re-
ported that electrical vagal stimulation controls inflammation and
improves organ function in sepsis [1–3]. Even sepsis accounts for
only 2 % of the hospitalizations; it makes up 17 % of in-hospital
deaths in the US. We reasoned that nerve stimulation may control
immunological stress during surgery, a major cause contributing sep-
sis during hospitalization.
Materials and methods: Here, we report a prospective double-
blinded pilot trial to analyze whether intraoperative transdermal
nerve stimulation prevents trauma, physiological and immunological
stress during surgery.
Results: Transdermal nerve stimulation was performed with elec-
troacupuncture on anesthetized patients, and blood samples were
collected under anesthesia to avoid any placebo interference. Sub-
jects with electroacupuncture required 60 % less postoperative an-
algesic, but they had pain scores similar to that in the control
patients. Electroacupuncture prevented postoperative hypergly-
cemia and attenuated serum ACTH in the older and heavier group
of patients. From an immunological perspective, electroacupunc-
ture did not affect the protective immune responses to surgical
trauma including the induction of IL6 and IL10. The most signifi-
cant immunological effect of electroacupuncture was enhancing
TGFβ1 production during surgery in the older and lighter group of
patients.
Conclusions: These results suggest that intraoperative electroacu-
puncture can reduce postoperative use of analgesic and improve im-
mune and stress responses to surgery in anesthetized patients.
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Background: Septic shock is a major cause of death among the crit-
ically ill. Incompletely understood biology has lent itself to be ex-
plored at the genome level. Availability of genome-wide expression
data from different studies on septic shock empowers the quest for
pathways of interest by integration and meta-analysis of multiple
data sets.
Materials and methods: Electronic search was performed on medical
literature (PubMed) and genome-wide gene expression databases
(National Centre for Biotechnology Information Gene Expression
Omnibus). Human studies of transcriptomic analysis of circulating
leukocytes were selected. Systematic analysis was conducted to de-
tect pathways differentially regulated in septic shock. Additionally
coexpression network analysis was conducted.
Results: Osteoclast differentiation was consistently up-regulated in
septic shock. As shown in Fig. 13, principal components analysis
clearly distinguishes pathway expression in septic shock from sepsis.
Conclusions: A multi-gene expression signature differentiated septic
shock from the milder form of sepsis. This deepens our understand-
ing of disease biology of septic shock and is of potential value for
clinical management.
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Fig. 13 (abstract P7). Three dimensional plot of Principal
Component Analysis (PCA) of Septic Shock (in red) and sepsis (in
blue) studies. Each point represents the fold-change in gene expres-
sion of the Osteoclast Differentiation Pathway in a single study. The
septic shock and sepsis studies appear well separated from each
other in the three dimensional space. The sepsis studies clearly show
more intra-group heterogeneity compared to septic shock studies
that form a small tight cluster
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Background: The mortality rate for critically ill septic patients remains
unacceptably high. Timely administration of appropriate antimicro-
bials is the cornerstone of management, and achieving therapeutic
levels is essential for ensuring treatment efficacy and preventing the
development of drug-resistant pathogens [1]. The purpose of this art-
icle is to review the literature pertaining to antibiotic dosing in septic
patients on the intensive care unit, and to explore whether thera-
peutic drug monitoring (TDM) may help to optimise management of
this important patient group.
Materials and methods: A literature search was performed using Web
of Science and PubMed databases. Search terms included ‘antibiotic
level*’, ‘antibiotic dos*’, ‘therapeutic drug monitoring’ and ‘sepsis’. The ref-
erence lists of selected papers were also reviewed for relevant articles.
Results: Critically ill septic patients exhibit a multitude of pathophysio-
logical changes which affect drug handling, making achievement of
optimum antibiotic dosing difficult [2]. Ample data is available to sug-
gest that a worrying number of these patients do not receive thera-
peutic antibiotic doses [3–5]. Notably, the ‘Defining Antibiotic Levels in
Intensive Care Unit Patients’ study measured serum concentrations of
β-lactams in 384 patients across 68 hospitals in 10 countries. In 16 % of
patients concentrations did not exceed the minimum inhibitory con-
centration, and this correlated with a poorer clinical outcome.[6] Simi-
larly, a study measuring serum β-lactam concentrations in 80 patients
found sub-therapeutic levels in the majority [7], and a 2014 study of 30
septic patients found linezolid levels to be sub-therapeutic in 63 % and
toxic in 7 % [8]. Several studies suggest that TDM may lead to signifi-
cant improvements in drug concentrations [9–10], although relatively
few randomised controlled trials (RCT) have been conducted. One RCT
compared TDM with standard dosing in 41 patients treated with piper-
acillin/tazobactam. Adequate drug concentrations were found in a sig-
nificantly higher proportion of patients in the intervention than the
control group. Mortality, however, did not differ significantly (althoughthis was not a primary endpoint, and the study was not powered to de-
tect this) [11]. Similar findings were reported from an RCT comparing
TDM with standard dosing in 32 patients with neutropenic sepsis
treated with piperacillin/tazobactam [12].
Conclusions: Based on the available evidence, it would seem that a
worryingly high proportion of patients are receiving inadequate anti-
biotic doses, increasing the likelihood of treatment failure and the
development of drug-resistance. Therapeutic drug monitoring offers
a potential solution. A number of studies have demonstrated a bene-
fit in pharmacokinetic/pharmacodynamic parameters. It remains un-
clear whether this translates to an improvement in clinical outcomes,
and further research is required.
References
1. Timsit JF, Perner A, Bakker J, Bassetti M, Benoit D, Cecconi M, Curtis JR, Doig
GS, Herridge M, Jaber S et al. Year in review in Intensive Care Medicine 2014:
III. Severe infections, septic shock, healthcare-associated infections, highly re-
sistant bacteria, invasive fungal infections, severe viral infections, Ebola virus
disease and paediatrics. Intensive Care Med. 2015;41:575–588.
2. Roberts JA, Norris R, Paterson DL, Martin JH. Therapeutic drug monitoring
of antimicrobials. Br J Clin Pharmacol. 2012;73:27–36.
3. Tsai D, Lipman J, Roberts JA. Pharmacokinetic/pharmacodynamics consid-
erations for the optimization of antimicrobial delivery in the critically ill.
Curr Opin Crit Care. 2015;21:412–420.
4. Varghese JM, Roberts JA, Lipman J. Pharmacokinetics and pharmacodynam-
ics in critically ill patients. Curr Opin Anaesthesiol. 2010;23:472–478.
5. Felton TW, Hope WW, Roberts JA. How severe is antibiotic pharmacoki-
netic variability in critically ill patients and what can be done about it?
Diagn Microbiol Infect Dis. 2014;79:441–447.
6. Roberts JA, Paul SK, Akova M, Bassetti M, De Waele JJ, Dimopoulos G, Kau-
konen KM, Koulenti D, Martin C, Montravers P et al. DALI: defining anti-
biotic levels in intensive care unit patients: are current β-lactam antibiotic
doses sufficient for critically ill patients? Clin Infect Dis. 2014;58:1072–1083.
7. Taccone FS, Laterre PF, Dugernier T, Spapen H, Delattre I, Wittebole X, De
Backer D, Layeux B, Wallemacq P, Vincent JL et al. Insufficient β-lactam
concentrations in the early phase of severe sepsis and septic shock. Crit
Care. 2010;14:R126.
8. Zoller M, Maier B, Hornuss C, Neugebauer C, Döbbeler G, Nagel D, Holdt
LM, Bruegel M, Weig T, Grabein B et al. Variability of linezo! lid concentra-
tions after standard dosing in critically ill patients: a prospective observa-
tional study. Crit Care. 2014;18:R148.
9. Duszynska W, Taccone FS, Hurkacz M, Kowalska-Krochmal B, Wiela-
Hojeńska A, Kübler A. Therapeutic drug monitoring of amikacin in septic
patients. Crit Care. 2013;17:R165.
10. Tröger U, Drust A, Martens-Lobenhoffer J, Tanev I, Braun-Dullaeus RC,
Bode-Böger SM. Decreased meropenem levels in Intensive Care Unit pa-
tients with augmented renal clearance: benefit of therapeutic drug moni-
toring. Int J Antimicrob Agents. 2012;40:370–372.
11. De Waele JJ, Carrette S, Carlier M, Stove V, Boelens J, Claeys G, Leroux-
Roels I, Hoste E, Depuydt P, Decruyenaere J et al. Therapeutic drug
monitoring-based dose optimisation of piperacillin and meropenem: a
randomised controlled trial. Intensive Care Med. 2014;40:380–387.
12. Sime FB, Roberts MS, Tiong IS, Gardner JH, Lehman S, Peake SL, Hahn U,
Warner MS, Roberts JA. Can therapeutic drug monitoring optimize expos-
ure to piperacillin in febrile neutropenic patients with haematological
malignancies? A randomized controlled trial. J Antimicrob Chemother.
2015;70:2369–2375.
P9
Pandemic of Escherichia coli clone O25: H4-ST131 producing
CTX-M-15 extended spectrum- β- lactamase- as serious cause of
multidrug resistance extraintestinal pathogenic E. coli infections
in India
Savita Jadhav, Rabindra Nath Misra, Nageswari Gandham,
Kalpana Angadi, Chanda Vywahare, Neetu Gupta, Deepali Desai
Department of Microbiology, Dr. D.Y.Patil Medical College, Hospital and
research Centre (Dr D.Y.Patil Vidyapeeth Pune) Pimpri-Pune 411018, India
Correspondence: Savita Jadhav (patilsv78@gmail.com) – Department
of Microbiology, Dr. D.Y.Patil Medical College, Hospital and research
Centre ( Dr D.Y.Patil Vidyapeeth Pune) Pimpri-Pune 411018, India
Critical Care 2016, 20(Suppl 1):P9
Critical Care 2016, Volume 20 Suppl 1 Page 7 of 11Background: Antimicrobial resistance has emerged as an important
determinant of outcome for patients in the intensive care unit
(ICU). In recent years infections due to extraintestinal pathogenic
Escherichia coli (ExPEC) predominantly E.coli sequence type 131
(ST131) is of great concern due to significant morbidity and mortal-
ity [2] a major clone linked to the spread of the CTX-M-15 extended
spectrum- β- lactamase (ESBL) resistance is growing concern in the
ICU patient’s population as it has been directly related with fluoro-
quinolone resistance and coresistance to aminoglycosides and
trimethoprime-sulfamthoxazole, consequently delays in appropriate
therapy, higher costs, and increased use of “last resort” antimicro-
bials e.g. carbapenemase to treat life threatening infections [3,4]. E.
coli ST131 lineage among ExPEC is leading cause of community as
well as hospital acquired urinary tract infections (UTIs) and also fre-
quently encountered in soft tissue infections, blood stream infec-
tions (BSIs) and neonatal meningitis [1–4]. It is of major awareness
to investigate its prevalence in countries such as India and to deter-
mine antibiotic resistance, virulence factors, associated clinical risk
factors and potential genetic architecture of E. coli ST131.
Materials and methods: 314 phenotypically ESBL producing ExPEC
were isolated from various clinical samples admitted in various ICUs,
received in the clinical microbiology laboratory of tertiary care hos-
pital India. Molecular genotyping were confirmed by allele-specific
PCR targeting the rfbO25 subgroup gene locus, molecular detection
of metallobetalactamases by using genes bla OXA, bla KPC, bla VIM,
and bla NDM-1. Rep-PCR fingerprinting was done for phylogenetic
analysis [1–5].
Results: Of the total of 314 phenotypically ESBL producing ExPEC,
180 (57.32 %) were positive for O25:H4-ST131 CTX-M-15 of which
155 (86.11 %) co-resistant to aminoglycosides, fluroquinilones
162 (92 %) and co-trimaxazole 138 (76.66 %) and 53 (29.44 %) were
MBL positive by molecular detection. 70.34 % were from Urinary
tract infections and 15.95 % were from BSIs and 10.19 % were from
soft tissue infections while 3.50 % were from neonatal meningitis.
Living in long-term care facility was positively associated with clin-
ical isolates of ST131 E. coli while bacteremia caused by this clone
was associated with secondary bacteremia from spontaneous focal
infections. Nitrofurantoin found 100 % susceptible in all urinary iso-
lates. Rep-PCR fingerprinting were distinct from UPEC isolated from
global origins. pap, sfa, aer, hly were detected predominant viru-
lence factor.
Conclusions: Our Meticulous analysis form significant baseline data-
set towards understanding of E. coli clone O25: H4-ST131 producing
CTX-M-15 from India. Such observations is necessary throughout the
country to control this worsen situation for implementation of best
infection control practices.
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Background: Acute bacterial meningitis (ABM) is a serious and often
life threatening disease. Due to the proximity of inflammation to the
brain, it can cause substantial neurological sequelae in survivors. The
severity of illness and the required treatment vary according to the
pathogen. In most cases it is difficult to distinguish between ABM
and other types of central nervous system infections, including those
caused by viruses. Therefore, early diagnosis and an effective treat-
ment regimen are still perceived as major challenges.
Materials and methods: Cerebrospinal fluid (CSF) from patients suf-
fering from ABM (n = 26), viral meningitis (VM) (n = 19), Lyme neurobor-
reliosis (n = 7) and headaches without any infections (n = 38) were
grouped on the basis of the disease and analyzed using tandem mass
spectrometry (LC-MS/MS) in data-dependent-acquisition (DDA) mode.
Results: A unique protein profile was found in each patient group
along with a few commonly up-regulated proteins. 59 proteins were
found to be affected in ABM, 22 proteins in VM and 7 in neuroborre-
liosis (p ≤ 0.05). A difference in the protein profile in between patient
groups was also observed. Neutrophil proteins such as neutrophil
elastase (NE) and myeloperoxidase (MPO) were up regulated only in
case of ABM in comparison with the other groups. This is in accord-
ance with the fact that neutrophils are the prime cells that are in-
volved in the defense against bacteria.
Conclusions: Our findings suggest that by using DDA-based mass
spectrometry, a unique pathogen-specific protein profile of the CSF
can be detected during meningitis. This may lead to early diagnosis
and better treatment options.
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Background: Despite advances in medicine, identification of sepsis
from non-infectious systemic inflammatory conditions such as trauma,
pancreatitis remains a challenging task for clinicians. Sepsis and trauma
are both found to be associated with hypocholestrolemia and inflam-
mation. Various studies have assessed and documented the prognostic
role of hypolipidemia and procalcitonin in diagnosis and prognosis of
sepsis; but in the rural setting, estimation of PCT is not easily available.
Hence, we elucidated the usefulness of serum lipid profile as compared
to procalcitonin in diagnosis of sepsis and trauma in the ICU.
Materials and methods: Serum total cholesterol (TC), high-density
lipoprotein cholesterol(HDL-C), low-density lipoprotein cholester-
ol(LDL-C) and PCT were measured in 121 community acquired sepsis
patients and 31 trauma patients at admission to ICU. SPSS version 17
was used for statistical analysis. Mann Whitney U test was applied to
determine the significance between two groups and receiver operat-
ing characteristic (ROC) curves were plotted; best cut off points were
derived. Sensitivity, specificity, positive predictive value (PPV) and
negative predictive value (NPV) were calculated.
Results: Median levels of TC, HDL-C, LDL-C were significantly lower
whereas PCT levels were significantly higher in sepsis group as com-
pared to trauma group (Table 4).
Critical Care 2016, Volume 20 Suppl 1 Page 8 of 11Among sepsis group, 33 patients had HDL below detection limit and
18 patients had LDL below detection limit. Further, ROC curve ana-
lysis between sepsis and trauma patients demonstrated a significant
area under the curve (AUC) for TC (0.661; 95 % CI: 0.56-0.74), HDL-C
(0.814; 95 % CI: 0.74-0.88), LDL-C (0.735; 95 % CI: 0.64-0.82), PCT
(0.873; 95 % CI: 0.81-0.93). At a cutoff point of 97.5 mg/dL, TC dem-
onstrated a sensitivity of 81 % and specificity of 50 %. However,
HDL-C at cut off 22.5 mg/dL demonstrated 90 % sensitivity, 70 %
specificity. LDL-C at cut off 52 mg/dL demonstrated similar sensitivity
of 76 % with specificity of 63 %. PCT showed best cut off at 4.72 ng/ml
with 73 % sensitivity, 87 % specificity. Correlation analysis demon-
strated a moderate negative correlation of PCT with TC(r = −0.507, p =
0.004) and HDL-C(r = −0.373, p = 0.039) in trauma and LDL-C in sepsis
(r = −0.283, p = 0.003) Fig. 14.
Conclusions: Amongst the markers evaluated, PCT and HDL-C are
the most effective in differentiating sepsis from trauma. At the same
time, the significance of correlations of PCT with cholesterol fractions
is maximum with HDL in trauma patients and LDL in sepsis patients.
Hence, in the rural setting where PCT estimation is not easily avail-
able, cholesterol fractions may be used to aid diagnosis.Table 4 (abstract P11). Median (interquartile range) of lipid
profile and procalcitonin levels in sepsis and trauma group at
the time of admission








96 (66–141) 124 (99–162) 0.006
HDL (mg/dl) 16 (8–25) 29 (25–37) 0.001
LDL (mg/dl) 31 (19–51) 58.5 (34–77.2) <0.001
PCT (ng/ml) 16.6 (4–92) 1.25 (0.44-3.97) <0.001
p value <0.005 considered significant
Fig. 14 (abstract P11). Receiver Operating Characteristic analysis
Curve for Lipid profile and Procalcitonin in sepsis versus trauma
patients. a Lipids. b ProcalcitoninP12
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Background: Heparin binding protein (HBP) is released from neutro-
phils early in the immune response, which leads to sepsis. It is a very
promising predictive biomarker for the development of sepsis and
plasma levels are associated with development of organ failure in pa-
tients. Heparin is a drug typically used as an anticoagulant however
it has recently been shown to affect many different systems, includ-
ing inflammation. HBP binds very strongly to heparin and some stud-
ies have suggested that the use of heparin can have beneficial
effects in sepsis. Therefore we hypothesized that HBP plays a causa-
tive role in the development of vascular leakage and AKI in sepsis
and that heparin derivatives can be used to block these effects.
Materials and methods: In-vitro, cultured endothelial and renal epi-
thelial cells were treated with recombinant HBP. Trans-endothelial
electrical resistance (TEER) was used to evaluate permeability of
endothelial cell monolayers. IL-6 ELISA was used to evaluate HBP-
induced inflammation in renal cells. Recombinant HBP was also
injected into mice and scanning electron microscopy used to evalu-
ate plasma leakage and inflammation. Administration of different
heparin derivatives was used to block HBP-induced effects on perme-
ability and IL-6 release in vitro and plasma leakage in the lungs and
kidneys in-vivo.
Results: TEER showed that HBP significantly (P < 0.001) increased the
permeability of endothelial cell monolayers. HBP also induced the re-
lease of IL-6 from renal cells (P < 0.01). This suggests that HBP plays
causative roles in the development of vascular leakage and renal in-
flammation. HBP was also injected into mice and scanning electron mi-
croscopy revealed that it induced plasma leakage in the lungs and the
kidneys. Administration of different heparin derivatives blocked the
ability of HBP to induce permeability (p < 0.001) and IL-6 release in-vitro
(P < 0.001) and plasma leakage in the lungs and kidneys in-vivo.
Conclusions: Heparin binding protein (HBP) appears to play a causa-
tive role in sepsis and heparin compounds may be potential new
therapeutics in its treatment.
P13
Hypothalamic impairment is associated with vasopressin
deficiency during sepsis
Luis Henrique Angenendt da Costa1, Nilton Nascimentos dos Santos
Júnior1, Carlos Henrique Rocha Catalão1, Maria José Alves da Rocha2
1Department of Neurosciences and Behavioral Sciences, Ribeirão Preto
Medical School, University of São Paulo, Ribeirão Preto, Brazil;
2Department of Morphology, Physiology and Basic Pathology, School of
Dentistry of Ribeirão Preto, University of São Paulo, Ribeirão Preto, Brazil
Correspondence: Luis Henrique Angenendt da Costa
(luis.angenendt@gmail.com) – Department of Neurosciences and
Behavioral Sciences, Ribeirão Preto Medical School, University of São
Paulo, Ribeirão Preto, Brazil
Critical Care 2016, 20(Suppl 1):P13
Background: Clinical and experimental studies have shown many
hormonal alterations during sepsis. Considering vasopressin (AVP) se-
cretion, in the early phase of sepsis its plasma concentration is in-
creased. However, during the pathophysiological process the plasma
levels remain inadequately low, despite of persistent hypotension.
One of the hypotheses suggested for this relative deficiency is the
apoptosis of vasopressinergic neurons in hypothalamus. Our object-
ive was to identify elements involved in the hypothalamic cellular
death and evaluate the modifications of glial cells and blood–brain-
barrier (BBB) during sepsis.
Fig. 15 (abstract P14).
Fig. 16 (abstract P14).
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to sepsis by cecal ligation and puncture (CLP) or non-manipulated
(naïve), as control and then divided in two groups. In the first one,
they were perfused and brains were collected for immunohistochem-
istry. In another one they were decapitated for blood collection and
further plasma interferon-gama (IFN-γ) analysis by ELISA. Brain was
also removed for apoptosis-related proteins expression analysis in
the hypothalamus or in the supraoptic (SON) and paraventricular
(PVN) nuclei by western blot. A third one was separated for the in-
vestigation of BBB permeability.
Results: Despite of increased immunostaining for CD8 and MHC-I in
the SON of septic animals, we did not find evidence of cell death
mediated by immune cells. In the SON and PVN of septic animals,
the expression of proteins involved in the activation of the extrinsic
apoptosis pathway (tBID, cleaved caspase-8) was not altered, whereas
anti-apoptotic factors related to the intrinsic pathway (BCL-2, BCL-xL)
were decreased. In the SON of these animals, microglia assumed a
morphology related to its activation, associated with the increase of
plasma IFN-γ. There was a transitory breakdown of BBB in hypothal-
amus after 6 hours following CLP.
Conclusions: The results indicate that the intrinsic apoptosis pathway
seems to be responsible for the cell death observed in vasopressiner-
gic nuclei and this condition is associated with microglial activation
and BBB leaking.
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Background: Since decades worldwide investigators are searching re-
liable sepsis markers for prognostic and diagnostic evaluation of crit-
ically ill patients. Our group has already assessed sCD25 and IL-10 as
dependable sepsis markers. Recently presepsin (soluble CD14 sub-
type, sCD14-ST) has been shown to increase in plasma of patients
with sepsis. Here we evaluated the role of presepsin (PRES) in pre-
dicting outcome of critical septic patients; SOFA, procalcitonin (PCT)
and C-reactive protein (CRP) were also assessed in parallel.
Materials and methods: Critical patients admitted to the Unit of In-
tensive Care (ICU) of the University Hospital of Catanzaro (Italy) were
sequentially enrolled into this observational prospective study, if a
sepsis was clinically suspected; healthy volunteers were also included
as controls. The SOFA score was assessed at the time of ICU admis-
sion. Clinical and microbiological data including blood culture were
collected periodically. Based on 28 days survival, subjects were strati-
fied in survivors and non-survivors. Plasma and serum samples were
collected at multiple time points; samples were tested for presepsin
(PATHFAST Presepsin assay), procalcitonin (VIDAS BRAHMS PCT), C-
reactive protein and IgG4 (BNTM II System immunonephelometry). A
statistical analysis was carried out by ANOVA plus PLSD Fisher’s test.
Results: At the admission SOFA scores were found significantly higher
(p < 0.001) in nonsurvivor patients vs. survivor subjects (Fig. 15).
Levels of presepsin were significantly more elevated at T-0 (p = 0.0007)
(Fig. 16), at T-1 (p < 0.0001) and at T-2 (p < 0.0001) in non-survivors vs.
survivors at the same time. Presepsin concentrations were found signifi-
cantly increased at T-0 (p = 0.0073), T1 (p = 0.0111) and T2 (p = 0.0167)
in blood culture-positive in comparison to culture-negative patients at
the same time.
In culture-positive patients at T-0 both PCT and CRP levels, were found
significantly enhanced vs. culture-negative with p values of 0.0353 and
0.0331, respectively. Presepsin data from dead/alive individuals weresubjected to ROC analysis, which demonstrated an excellent accuracy
and significant AUROCC (p < 0.0001) at all the times evaluated; CRP did
not exhibit a significant AUROCC at any time and PCT showed a signifi-
cant AUROCC (p < 0.0001) only at T-2. Levels of IgG4 at T-0 were signifi-
cantly (p < 0.04) higher in non-survivors when compared with survivors
and with healthy subjects.
Conclusions: Presepsin may increase SOFA contribution to manage-
ment decisions and level of treatment in studied patients. Markers
belonging to acquired immunity deserve further evaluation. Presep-
sin appeared a reliable prognostic tool and revealed also an interest-
ing diagnostic value.P15
Safety and efficacy of gelatin-containing solutions versus
crystalloids and albumin - a systematic review with quantitative
and qualitative summaries
Christiane Hartog1,2, Claudia Moeller,1 Carolin Fleischmann,1,2 Daniel
Thomas-Rueddel,1 Vlasislav Vlasakov,1 Bram Rochwerg,3 Philip Theurer,1
Konrad Reinhart,1,2
1Department for Anesthesiology and Intensive Care, Jena University
Hospital, Jena, Germany; 2Center for Sepsis Control and Care, Jena
University Hospital, Jena, Germany; 3Department of Medicine (Division of
Critical Care), McMaster University, Hamilton, Ontario, Canada
Correspondence: Christiane Hartog (Christiane.Hartog@med.uni-jena.de) -
Department for Anesthesiology and Intensive Care, Jena University
Hospital, Jena, Germany
Critical Care 2016, 20(Suppl 1):P15
Background: Gelatin solutions are regarded as fluid alternatives to
crystalloids or albumin to treat hypovolemia in the ICU. However, lit-
tle is known about their safety and efficacy. In parts of the world
their use increased as hydroxyethyl starches were restricted due to
safety concerns.
Materials and methods: Systematic review and meta-analysis of ran-
domised and non-randomised controlled trials. Data sources included
the Cochrane Central Register of Controlled Trials, Medline, Embase,
Indmed, MedCarib, AJO, AIM, IMEMR, WHOLIS, LILACS, WPRIM,
IMSEAR, Google Scholar, Grey Literature, German National Library,
Critical Care 2016, Volume 20 Suppl 1 Page 10 of 11the German Pharmacovigilance Database and Clinical Trials Regis-
tries, until August 2015. Trials were included if they compared gelatin
with either crystalloid or human albumin for the treatment of hypo-
volemia and reported data on defined outcomes. Uncontrolled stu-
dies which reported “extravascular uptake” were also included. No
language was excluded. Risk of bias was assessed using the
Cochrane tool for RCTs and the Ottawa Newcastle scale for observa-
tional studies. Certainty of evidence was assessed using the GRADE
methodology.
Results: 60 studies were included, consisting of 30 RCTs with 3629
patients, 8 non-randomised studies with 10827 patients and 22 ani-
mal studies. For those receiving gelatin, the relative risks (RR) were as
follows: for mortality (RR 1.18, 95 % CI 0.98-1.41, 16 RCTs, 2525 pa-
tients; low certainty in evidence), requiring allogenic blood transfu-
sion (RR 1.25, 95 % CI 0.95-1.64, 8 RCTs, 744 patients; low certainty in
evidence), acute kidney injury (RR 1.32, 95 % CI [0.61, 2.87], 3 RCTs,
212 patients, very low certainty in evidence), anaphylactic adverse ef-
fects (RR 2.18, 95 % CI 0.87-5.44, 3 RCTs 872 patients, very low cer-
tainty of evidence). Mean crystalloid-to-colloid ratio was 1.44 (±0.31,
6 RCTs). Four observational controlled studies (9403 patients, low risk
of bias) all found an increased risk for acute kidney injury (AKI) or
need for renal replacement therapy (RRT). Reported elimination defi-
cits indicating extravascular uptake ranged from 17 to 31 % (3 non-
randomised, uncontrolled cohort studies, 95 subjects). Eleven of thir-
teen animal studies provided evidence of histopathological changes
in the kidneys after gelatin administration.
Conclusions: Despite the poor quality of published evidence, the
meta-analysis of RCTs demonstrated a trend towards increased mor-
tality and bleeding while observational studies suggested an in-
creased rate of renal failure. Plasma expansion with gelatin is not
associated with a relevant benefit. In the absence of evidence from
adequately designed RCTs showing these solutions to be safe and ef-
fective, gelatin plasma expanders should no longer be used outside
the research setting.
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Background: Bacterial sepsis in humans is a common cause of illness
and death worldwide, accounting for 60-80 % of deaths in deve-
loping countries and 20-30 % of deaths in the United States [1–3].
Overwhelming inflammation associated with Gram-negative sepsis
(endotoxemia; lipopolysaccharide [LPS]) can lead to organ failure and
death, and there is a critical need to identify therapy that will target
this inflammation. Recently, horses have been identified as an im-
portant, emerging model for human sepsis, given that sepsis occurs
naturally and is a leading cause of illness and death in both neonatal
and adult horses [4]. Similar to sepsis in humans, horses develop
sepsis-associated acute lung injury, septic peritonitis from bowel dis-
ruption, and bacteremia [4–8]. Studies have shown that mesenchy-
mal stem cells (MSC) can decrease lymphocyte proliferation and
downregulate pro-inflammatory cascades [9,10]. Specifically, MSC
have been shown to secrete IL-6 and PGE2 in response to TNF-α,
which results in decreased lymphocyte proliferation and thus, down-
regulation of pro-inflammatory cascades [11,12]. Importantly, equine
MSC are easily harvested from peripheral blood, which allows for
simple isolation and minimal donor morbidity [13]. We hypothesized
that addition of equine peripheral blood MSC (PB-MSC) to cultures ofequine mononuclear cells would result in increased production of IL-6,
PGE2 and TXA2, and inhibition of TNF-α and IL-8 production following
LPS stimulation.
Materials and methods: We investigated the immunomodulatory
properties of PB-MSC following stimulation with 100 pg/mL of lipo-
polysaccharide (LPS). Equine PB-MSC were added to equine mono-
cyte cultures at ratios of 1:1, 1:2, 1:5, 1:10, and 1:100 (monocytes:PB-
MSC), and supernatants were collected 12 hours after the onset of
LPS treatment. Culture supernatant concentrations of the pro-
inflammatory cytokines TNF-α, IL-6 and IL-8 and the eicosanoids
PGE2 and TXA2 were evaluated by enzyme-linked immunosorbent
assays (ELISA).
Results: As expected, the addition of equine PB-MSC to equine
monocyte cultures resulted in increased concentrations of IL-6, PGE2
and TXA2, and decreased concentrations of TNF-α at 12 hours post-
LPS stimulation (Fig. 17). There was no effect of equine PB-MSCs on
IL-8 concentrations 12 hours post-LPS stimulation (data not shown).
Conclusions: Equine PB-MSC appear to respond in vitro to LPS-
stimulated equine monocytes by facilitating increases in cytokines
that suppress lymphocyte proliferation and inhibit selective pro-
inflammatory cytokines. Subsequent studies will evaluate lymphocyte
responses in-vitro, as well as the safety and efficacy of equine PB-
MSC in an in-vivo equine model of endotoxemia. These results have
important implications for treatment of sepsis in horses and other
species.
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Critical Care 2016, 20(Suppl 1):P17Background: The frequency of early (within the first three days of on-
set) sepsis-associated coagulopathy (SAC) and its association with
clinical outcomes varies depending on the definition(s) of coagulopa-
thy. Furthermore, the frequency of SAC may have decreased with
more effective use of sepsis bundles (early antibiotics, fluids, and va-
sopressors). Accordingly, we sought to determine the frequency and
outcome of early SAC.
Materials and methods: We reviewed all patients admitted to the
medical-surgical Intensive Care Unit (ICU) of St. Paul’s Hospital, a tertiary
care hospital in Vancouver, Canada from January 2011 to July 2013. We
included patients who met SAC inclusion criteria: sepsis and platelet
count less than 150,000 (or a decrease of at least 30 %) and Inter-
national Normalized ratio (INR) greater than 1.2 within the first three
days of onset of sepsis. We assessed the presence and severity of SAC
and the association of SAC with hospital mortality and need for vaso-
pressors, ventilation and renal replacement therapy (RRT).
Results: Of 1,397 ICU admissions 517 had sepsis and of these, 373
(27 % of ICU admissions, 72 % of septic patients) had at least 1 INR and
platelet count at any point from day 1 to 3 of ICU admission. 20 to
35 % of septic patients met various criteria for SAC. Presence of SAC at
12 hours or at 24 hours was associated with significantly increased
mortality (Odds Ratio (OR) = 2.3 & 1.94 at 12 and 24 hrs respectively)
and need for vasopressors (OR = 4.6 & 6.4), ventilation (OR = 1.68 &
2.13) and RRT (OR = 1.71 & 2.94) in both unadjusted and adjusted ana-
lyses. Increasing severity of the combination of abnormal INR and plate-
lets was associated with significantly higher mortality and greater need
for vasopressors and RRT but not ventilation. Increasingly abnormal INR
was associated with increasing mortality in a monotonic, increasing
fashion whereas only severe thrombocytopenia (platelets (<80,000) was
associated with significantly increased mortality.
Conclusions: SAC is common (20 – 35 % of septic patients) and is as-
sociated with increased mortality and need for vasopressors, ventila-
tion and renal replacement therapy. Accordingly, there is a need for
therapies that decrease the severity of SAC to attempt to decrease
mortality and organ dysfunction in sepsis.•  We accept pre-submission inquiries 
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